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CopyrightAntiangiogenic Activity of Xanthomicrol and
Calycopterin, TwoPolymethoxylatedHydroxyflavones
in Both In Vitro and Ex VivoModelsHassan Abbaszadeh,1 Soltan Ahmad Ebrahimi1* and Maziar Mohammad Akhavan2
1Iran University of Medical Sciences, School of Medicine, Department of Pharmacology, Tehran, Iran
2Skin Research Center, Laboratory of Protein and Enzyme, Shahid Beheshti University of Medical Sciences, Tehran, IranOur previous studies had shown xanthomicrol and calycopterin, two plant-derived flavonoids, to have selective
antiproliferative activity against some malignant cell lines. The present study is focused on the investigation of
antiangiogenic potential of these two flavonoids, using in vitro and ex vivo models. Xanthomicrol and
calycopterin were found to have potent inhibitory effects on microvessel outgrowth in the rat aortic ring assay.
Xanthomicrol was able to completely block microvessel sprouting at 10μg/mL, and calycopterin suppressed
microvessel outgrowth by 89% at 5μg/mL. Suramin and thalidomide, used at 20μg/mL as positive controls,
inhibited microvessel formation by 23% and 64%, respectively. The flavones also inhibited endothelial cell tube
formation and human umbilical vein endothelial cell proliferation at 0.5, 5, and 10μg/mL. In order to delineate
the underlying mechanisms of antiangiogenic activity of these flavones, we investigated the influences of
xanthomicrol and calycopterin on expression of vascular endothelial growth factor (VEGF) and
basic-fibroblast growth factor (b-FGF) in endothelial cells. These flavones were able to inhibit VEGF expression
at 0.5, 5, and 10μg/mL, but they had little or no effect on b-FGF expression. These findings suggest that
xanthomicrol and calycopterin possess potent antiangiogenic activities, which may be due to their inhibitory
influences on VEGF expression. Copyright © 2014 John Wiley & Sons, Ltd.
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Many flavonoids have been demonstrated to have
in vitro cytotoxic activity against various cell lines and
have therefore been proposed as anticancer drugs or
precursors of such agents. However, a large number of
the flavonoids studied have nonselective cytotoxic
activity against many cell lines, malignant or otherwise
(Chang et al., 2008). Studies involving structure–activity
relationship of flavonoids have provided evidence that
methoxylation of these compounds can change the
pattern of their in vitro antiproliferative activity against
various cell lines and, in some cases, such substitutions
have rendered the molecules highly selective against
specific cell lineages (Walle, 2007). Xanthomicrol and
calycopterin (Fig. 1) are two such flavonoids isolated
from Dracocephalum kotschyii Boiss (Jahaniani et al.,
2005; Faham et al., 2008). Dracocephalum kotschyii
Boiss is a native Iranian medicinal plant with analgesic,
antispasmodic, and anticancer properties and has been
used in traditional medicine for many years (Jahaniani
et al., 2005). Research in our laboratory (Moghaddam
et al., 2012) showed that many of the flavonoids
obtained from this plant had some cytotoxic activity;
however, those with one hydroxyl group and no
methoxy groups, for example, luteoline and apigenine,
were nonselectively cytotoxic against all cell lines tested.ondence to: Soltan Ahmad Ebrahimi, Iran University of Medical
chool of Medicine, Department of Pharmacology, Tehran, Iran.
rahimi.sa@iums.ac.ir
© 2014 John Wiley & Sons, Ltd.In contrast, xanthomicrol and calycopterin, which had
no hydroxyl groups and were trimethoxylated and
tetramethoxylated, respectively, showed selective
cytotoxic activity against some cell lines with little effect
on human fetal foreskin fibroblast cells used as normal,
nonmalignant control. In the same study, we reported
that these compounds showed little preferential
cytotoxicity against WEHI-164 (murine fibrosarcoma)
cells in vitro. However, both compounds inhibited tumor
growth in mice transplanted with WEHI-164 cells
(data not shown).
Sometimes, lack of correlation of in vitro and in vivo
effects may induce research into alternative pharmaco-
logical effects. Genistein is an example in hand. It is
consumed in large quantities in soya-containing products
in the Far East, and it is thought to be the reason for lower
incidences of some cancers in Japanese and Chinese
populations compared with the rest of the world
(Banerjee et al., 2008). Although research had shown it
to have in vitro cytotoxic effects, pharmacokinetic studies
had shown it to have lower serum levels than would be
necessary for significant cytotoxic activity (Barnes,
1995). Further research showed that it inhibited prolifera-
tion of endothelial cells at pharmacokinetically observed
serum concentrations (Barnes, 1995), suggesting an
antiangiogenic mechanism of action for this isoflavone.
Because of structural similarities to genistein, other
flavonoids could also act by inhibiting endothelial cell
proliferation. Therefore, xanthomicrol and calycopterin
may have an antiproliferative effect on endothelial cells
and affect angiogenesis, in vivo. Angiogenesis, the gen-
eration of new blood vessels by sprouting of pre-existingReceived 3 February 2014
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Figure 1. Chemical structures of xanthomicrol and calycopterin.
1662 H. ABBASZADEH ET AL.vessels, is an essential stage in both physiological
processes including reproductive function, embryonic
development, wound healing, and pathological states such
as diabetic retinopathy, psoriasis, chronic inflammations,
tumor growth, and metastasis (Carmeliet, 2003). On the
basis of the fact that a tumor cannot grow over a few cubic
millimeters without the generation of new blood vessels
(Folkman, 1975), angiogenesis must play a critical role in
the development of solid tumors and metastases. There-
fore, inhibition of pathological angiogenesis may represent
an effective strategy to suppress tumor progression.Angio-
genesis, a complex and multistage process, is mediated by
angiogenic factors, chemokines, angiogenic enzymes,
adhesion molecules, and endothelial cell receptors. Each
of these components can be targeted to develop agents
with antiangiogenic activity (Liekens et al., 2001). Vascular
endothelial growth factor (VEGF) appears to possess a
central role in generation of new blood vessels. VEGF
can interact with specific receptors (VEGFR) on endothe-
lial cells to initiate the intracellular processes necessary for
proliferation, adhesion, and migration of these cells, thus
promoting angiogenesis. Basic-fibroblast growth factor
(b-FGF) induces angiogenesis indirectly by increasing the
release of VEGF from many cell types (Liekens et al.,
2001; Cross and Claesson-welsh, 2001).
In this study, effects of xanthomicrol and calycopterin
on proliferation of human umbilical vein endothelial
cells (HUVECs) were first studied. In order to demon-
strate whether xanthomicrol and calycopterin had any
antiangiogenic effect, we used the rat aortic ring assay.
The inhibitory effects of these flavones on the formation
of tubular network of endothelial cells were also
studied. To determine if the effects of xanthomicrol and
calycopterin on the production of VEGF and b-FGF
mirrored the effects they had on cellular models of
angiogenesis, we measured the expression of VEGF and
b-FGF in endothelial cells.MATERIALS AND METHODS
Chemicals and reagents. 3-[4,5-dimethylthiazol-2-yl]-2,5
diphenyl tetrazolium bromide (MTT), suramin,
thalidomide, bovine serum albumin (BSA), Tween 20 were
purchased from Sigma-Aldrich (St. Louis, MD, USA).
HUVECs were supplied by Pasteur Institute (Tehran,
Iran). Fetal bovine serum (FBS)was purchased fromGibco
(Life Technologies, Dan Allen Way, Carlsbad, CA, USA).
Dimethyl sulfoxide (DMSO) was obtained from Merck
(Darmstadt, Germany). Rabbit polyclonal anti-VEGF, rab-
bit polyclonal anti-b-FGF, rabbit polyclonal anti-β-actin, and
goat anti-rabbit IgG-horseradish peroxidase were obtained
from Santa Cruz Co. (Santa Cruz, Biotechnology, Dry
Creek Rd, Paso Robles, CA, USA). All other reagentsCopyright © 2014 John Wiley & Sons, Ltd.were of ANALAR grade. All solvents used were of
HPLC grade.
Extraction and purification of xanthomicrol and
calycopterin from Dracocephalum kotschyii Boiss.
Xanthomicrol and calycopterin were extracted from
Dracocephalum kotschyii Boiss as reported previously
(Moghaddam et al., 2012). Briefly, 50 g of powdered
leaves of Dracocephalum kotschyii Boiss were extracted
with 400mL of ethyl acetate overnight by the Soxhlet
method. The resulting extract was concentrated at 40 °C
under vacuum. The dried extract was dissolved in chloro-
form, and then aliquots of the filtered chloroform fraction
were further extracted with equal volumes of ammonia
solution (pH11). The resulting aqueous phase was
acidified using concentrated HCl. The acidified solution
was extracted with ethyl acetate. Finally, the resulting
organic phase was concentrated at 40 °C under vacuum,
and the residue was kept at 20 °C until needed.
The resulting dried substance after liquid–liquid
extraction was subjected to semi-preparative reversed-
phase HPLC on a Macherey–Nagel 10μm Nucleosil,
column (2.5 × 5 cm), using an isocratic solvent system
consisting of 56% HCl 0.01M, 25% acetonitrile, and
19% methanol. The flow rate was set at 7mL/min. The
injection volume was 1.7mL, and the detector was set to
226 nm. Data acquisition was performed using an
Adventec PCI 1719 data acquisition card and an in-house
developed software. The identities of xanthomicrol and
calycopterin were confirmed by Nuclear Magnetic Reso-
nance (NMR) Spectroscopy, Mass Spectrometry (MS)
and Infrared Spectroscopy (IR) as reported previously
(Moghaddam et al., 2012).
Endothelial cell proliferation assay. The MTT assay was
used to determine the proliferation of endothelial cells
treated with xanthomicrol or calycopterin. HUVECs
weremaintained inDulbecco’sModified Eagle’sMedium
(DMEM; Gibco) supplemented with 5% FBS. Cells were
seeded onto 96-well culture plate at a density of 10,000
cell per well and allowed to attach overnight at 37 °C
under 5% CO2. The culture medium was aspirated, and
fresh medium containing vehicle (0.1% DMSO),
xanthomicrol (0.5, 5, and 10μg/mL), or calycopterin
(0.5, 5, and 10μg/mL) was added to each well. The plate
was then incubated for 72h at 37 °C under 5% CO2.
Thereafter, 20μL of MTT (Sigma) solution in deionized
water (5mg/mL) was added to each well and incubated
at 37 °C under 5% CO2 for 4 h. The resulting MTT
formazan was dissolved by the addition of 100μL of
DMSO per well. The absorbance was measured at
570 nm using a DynexMRXmicroplate reader (Sullyfield
Circle, Chantilly, VA, USA). Independent MTT tests
were repeated three times.
Rat aortic ring assay. Briefly, 48-well culture plates were
coated with 100μL of Geltrex (Gibco), which were
allowed to gel for 30min at 37 °C under 5% CO2.
Thoracic aortas were carefully excised from juvenile
male Wistar rats. After removal of fibroadipose tissue,
the aortas were dissected into 1-mm-long cross sections.
Each aortic ring was set on one Geltrex-coated well and
was then covered with an additional 100μL of Geltrex.
After the second layer of Geltrex had been placed,
the rings were covered with EGM-II Bulletkit mediumPhytother. Res. 28: 1661–1670 (2014)
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overnight at 37 °C under 5% CO2. Afterwards, the culture
medium was replaced with EBM-II (Clonetics, Lonza
Pharma, Maryland, USA) supplemented with 2%
FBS, 0.25μg/mL amphotericin B, and 10μg/mL
gentamicin (no Bulletkit was added). Each aortic section
was exposed to vehicle (0.5% DMSO), xanthomicrol (0.
25–10μg/mL), or calycopterin (0.25–5μg/mL). Control
rings were treated with 20μg/mL suramin or thalidomide
for 4 days and photographed under an inverted
microscope on the fifth day using an X4 objective. Pixel-
integrated density of the area of microvessel sprouting
was quantified by image analysis using Image J software
(developed at National Institutes of Health, USA).
Independent tests were repeated three times, using aortas
from three different rats.
Endothelial cell tube formation assay. Culture plates
with 48 wells were coated with 50μL of Geltrex and
allowed to gel at 37 °C under 5% CO2 for 30min.
HUVECs pre-treated with xanthomicrol or calycopterin
in EGM-II medium containing the vehicle (0.1%
DMSO), xanthomicrol (0.5, 5, and 10μg/mL), or
calycopterin (0.5, 5, and 10μg/mL) were seeded on
Geltrex-coated wells at 40,000 cell per well and incu-
bated at 37 °C under 5% CO2 for 20 h. Suramin as posi-
tive control was used at the concentration of 40μg/mL.
Afterwards, the cells were stained with calcein
acetoxymethyl ester (Gibco) and incubated at 37 °C
under 5% CO2 for 30min. To analyze the resulting
capillary-like structures, the area of tubular structures
in each well was photographed under a fluorescence
microscope using an X20 objective. The corresponding
area was measured as the length of endothelial cell tube
at five random positions using Image J software
(Yamamizu et al., 2013). Independent experiments were
repeated three times.
Preparation of cell lysates. The HUVECs were grown to
80% confluency in 75-cm2 tissue culture flasks in
DMEM medium supplemented with 5% FBS at 37 °C
under 5% CO2. Cells were exposed to DMEM with
vehicle (1% DMSO), xanthomicrol (0.5, 5, and 10μg/mL),
or calycopterin (0.5, 5, and 10μg/mL) and incubated at
37 °C under 5% CO2 for 48h. Thereafter, HUVECs were
serum starved and treated with xanthomicrol (0.5, 5, and
10μg/mL) or calycopterin (0.5, 5, and 10μg/mL) and
incubated at 37 °C and 5% CO2 for 24h. The cells were
trypsinized and washed in phosphate-buffered saline
(pH7.4). Cells were lysed by homogenizing in lysis buffer
containing proteases inhibitors and then centrifuged to
pellet cell debris. The resulting supernatants were frozen
at 80 °C. To determine protein concentrations of cell
lysates, bicinchoninic acid assay kit (Pierce) was applied
using BSA as standard.
Western blotting. The resulting cell lysates were used
for VEGF, b-FGF, and β-actin analysis. Briefly, proteins
were separated using sodium dodecyl sulfate polyacryl-
amide gel electrophoresis on a 15% w/v acrylamide
gel. Protein bands were transferred to a polyvinylidene
difluoride membrane. The blot was blocked for 1 h in
tris-buffered saline containing 0.1% v/v Tween 20
(TBS-T) and 5% non-fat dry milk. Membranes were
incubated with primary antibodies: rabbit polyclonalCopyright © 2014 John Wiley & Sons, Ltd.anti-VEGF, rabbit polyclonal anti-b-FGF, and rabbit
polyclonal anti-β-actin in TBS-T containing 5% non-fat
dry milk, overnight at 4 °C. After washing several times
in TBS-T, the blot was incubated with goat anti-rabbit
IgG-horseradish peroxidase in TBS-T for 1 h at room
temperature. After extensive washing, the bands were
detected using enhanced chemiluminescence plus kit
(Pierce Protein Biology Products, Thermo Scientific,
Rockford, IL, USA). The resulting chemiluminescence
was visualized by developing the X-ray-film. Densito-
metric analysis of protein bands was performed using
Quantity One Analysis software (Bio Rad, Alfred No-
bel Drive, Hercules, CA, USA). Independent tests were
repeated for each protein three times.RESULTS
Inhibition of HUVECs proliferation by xanthomicrol
and calycopterin
The MTT as an in vitro assay was applied to assess the
effects of xanthomicrol and calycopterin on proliferation
of endothelial cells. Xanthomicrol and calycopterin
inhibited endothelial cells growth in a concentration-
dependent manner after 72h of treatment as illustrated
in Fig. 2. At 10μg/mL, xanthomicrol and calycopterin
attenuated endothelial cells proliferation by 51% and
75%, respectively.Xanthomicrol and calycopterin blocked microvessel
sprouting in ex vivo rat aortic ring assay
In order to evaluate the antiangiogenic properties of
xanthomicrol and calycopterin, the influences of these
flavones on microvessel outgrowth from rat aorta
were examined using the aortic ring assay. Xan-
thomicrol and calycopterin showed potent inhibitory
effects on microvessel sprouting in a concentration-
dependent manner as presented in Fig. 3. The anti-
angiogenic effects of these flavones were stronger than
suramin and thalidomide used as positive controls.
Xanthomicrol completely inhibited microvessel out-
growth at 10μg/mL, whereas calycopterin suppressed
microvessel outgrowth by 89% at 5μg/mL. Suramin and
thalidomide at 20μg/mL inhibited sprouting of new
vessels by 23% and 64%, respectively.Xanthomicrol and calycopterin inhibited the endothelial
cell tube formation
To further characterize whether xanthomicrol and
calycopterin could block endothelial cell migration and
tubulogenesis, we examined their effects on capillary-
like structures formed by endothelial cells seeded on
Geltrex. Tubulogenesis was inhibited by these flavones
in a concentration-dependent fashion as shown in Fig. 4.
At 10μg/mL, xanthomicrol and calycopterin inhibited
three-dimensional tubular structures by 65% and 70%,
respectively, whereas suramin at 40μg/mL, used as a
positive control, inhibited tube formation by 80%.Phytother. Res. 28: 1661–1670 (2014)
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Figure 2. Concentration-dependent inhibition of HUVECs proliferation by xanthomicrol and calycopterin. The percentage of endothelial cell
proliferation for each xanthomicrol and calycopterin concentration was calculated relative to the vehicle control (0.1% DMSO). Each point
represents mean±SE, n=3 (*, p<0.05, compared with vehicle control).
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expression in endothelial cells
To obtain an insight into the mechanism of antiangiogenic
activities of xanthomicrol and calycopterin, the effects of
these flavones on VEGF expression in HUVEC cells were
evaluated. After 72h incubation with xanthomicrol (0.5, 5,
and 10μg/mL) or calycopterin (0.5, 5, and 10μg/mL),
the intracellular VEGF expression was decreased in a con-
centration-dependent manner (Fig. 5). Compared with
vehicle control, xanthomicrol and calycopterin, at
10μg/mL, reduced VEGF expression by 38% and 44%,
respectively. These flavones had little or no effect on
b-FGF expression in endothelial cells at the same
concentrations used for VEGF (Fig. 6).DISCUSSION
Many flavonoids have been tested for their cytotoxic
effects, and some have been found effective enough to
be of interest for developing new anticancer agents
(Chang et al., 2008). Although many flavonoids such
as 3-hydroxyflavone, apigenine, and luteoline are
cytotoxic across the board (Cao et al., 2002), that is,
having nonselective effects, it is increasingly clear thatCopyright © 2014 John Wiley & Sons, Ltd.some compounds in this vast group affect various cell
lines differently, suggesting selective mechanisms of
action. Also, there are discrepancies between the
cytotoxic activities seen in vitro and the effectiveness
of some of these compounds as potential antineoplastic
drugs in vivo (Cao et al., 2002). Xanthomicrol and
calycopterin are two examples of such flavonoids. They
are both polymethoxylated and appear to have selective
activity against some cell lines but have little effect on
many others. More interestingly, these compounds
showed in vivo activity against tumors induced in mice
using cell lines, against which they had little in vitro
activity. One possible mechanism that could explain
this was a putative antiangiogenic activity exhibited by
these compounds.
Tumor angiogenesis is essential for the progression of
a neoplasm from a dormant localized tumor to a deve-
loping tumor with the potential to metastasize
(Folkman, 2006). Therefore, agents with antiangiogenic
activity could be effective in controlling primary growth
and secondary metastatic tumors. Many bioactive
plant-derived compounds have been tested for their
antiangiogenic properties (Cao et al., 2002; Singh and
Agarwal, 2003; Sagar et al., 2006;Mojzis et al., 2007;Mojzis
et al., 2008). Consistent with previous preclinical studies,
plants that are rich in polyphenols tend to have
antiangiogenic properties.Phytother. Res. 28: 1661–1670 (2014)
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Figure 3. Concentration-dependent antiangiogenic activity of xanthomicrol and calycopterin in the rat aortic ring model. (a) Bar graphs of the
percentage of microvessel outgrowth relative to the vehicle control (0.5% DMSO) after treatment with xanthomicrol (0.25–10μg/mL),
calycopterin (0.25–5μg/mL), suramin (20μg/mL), or thalidomide (20μg/mL). Bars represent mean±SE, n=3 (*, p<0.05, compared with
vehicle control). Representative images of rat aortic rings treated with the vehicle control (b); xanthomicrol at (c) 0.25, (d) 0.5, (e) 2.5, (f) 5,
and (g) 10μg/mL; calycopterin at (h) 0.25, (i) 0.5, (j) 1, (k) 3, (l) 5μg/mL; 20μg/mL thalidomide (m); or 20μg/mL suramin (n). This figure is
available in colour online at wileyonlinelibrary.com/journal/ptr.
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1666 H. ABBASZADEH ET AL.Xanthomicrol and calycopterin inhibited HUVEC pro-
liferation in culture medium in a concentration-dependent
manner. The antiproliferative activity of xanthomicrol and
calycopterin appeared to reach a plateau around 10μg/mL.
The inhibition of endothelial cell proliferation at the
highest concentration of xanthomicrol and calycopterinCopyright © 2014 John Wiley & Sons, Ltd.used was not complete, which could be an indication of
cytostatic rather than cytotoxic activity of these flavones.
This could be of great significance for an antiangiogenic
agent because cytotoxicity against endothelial cells would
mean damage to blood vessels in non-tumor tissue. Also,
the inhibition ofHUVECcell proliferation by xanthomicrolPhytother. Res. 28: 1661–1670 (2014)
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Figure 4. Concentration-dependent inhibition of capillary-like tube formation in HUVECs by xanthomicrol and calycopterin. (a) Bar graphs
of the percentage of tubule network length relative to the vehicle control (0.1% DMSO) after treatment with xanthomicrol and
calycopterin at 0.5, 5, and 10 μg/mL or suramin (40 μg/mL). Bars represent mean ± SE, n=3 (*, p<0.05, compared with vehicle control).
Representative images of the effects of treatment with vehicle control (b); xanthomicrol at (c) 0.5, (d) 5, and (e) 10μg/mL; calycopterin at
(f) 0.5, (g) 5, and (h) 10 μg/mL; or 40 μg/mL suramin (i) on endothelial cell tubule formations. This figure is available in colour online at
wileyonlinelibrary.com/journal/ptr.
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Figure 5. Concentration-dependent inhibitory effects of xanthomicrol and calycopterin on VEGF expression in HUVECs. (a) Western blot of
HUVEC lysates treated with vehicle control (0.1% DMSO), xanthomicrol (0.5, 5, and 10μg/mL), or calycopterin (0.5, 5, and 10μg/mL), for
72h and stained for VEGF using rabbit polyclonal anti-VEGF antibody followed by chemiluminescent visualization. (b) Bar graphs of the per-
centage of VEGF expression relative to the vehicle control (0.1% DMSO) versus treatment of endothelial cells with xanthomicrol or
calycopterin at 0.5, 5, and 10μg/mL. Bars represent mean±SE, n=3 (*, p<0.05, compared with vehicle control).
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Figure 6. The effect of xanthomicrol and calycopterin on b-FGF expression in HUVECs. (a)Western blot of HUVEC lysates treatedwith vehicle con-
trol (0.1%DMSO), xanthomicrol (0.5, 5, and10μg/mL), or calycopterin (0.5, 5, and10μg/mL), for 72h and stained for b-FGFusing rabbit polyclonal
anti-b-FGF antibody followed by chemiluminescent visualization. Bar graphs of the percentage of b-FGF expression relative to the vehicle control
(0.1% DMSO) versus treatment of endothelial cells with xanthomicrol or calycopterin at 0.5, 5, and 10μg/mL. Bars represent mean±SE, n=3.
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1669ANTIANGIOGENIC POLYMETHOXYLATED FLAVONESand calycopterin occurred at much lower concentrations
than needed to inhibit proliferation cancer cell lines as
reported by Moghaddam et al. (2012). This is a similar
situation to that seen with genistein (Cao et al., 2002).
In order to see if this inhibitory effect on HUVEC
proliferation could induce angiogenesis inhibition
in a more pathologically or physiologically relevant
situation, we studied the effects of these two flavonoids
using the rat aortic ring assay. For various reasons, rat
aortic ring assay is a good model of angiogenesis: the en-
dothelial cells within the aortic explants are not in a pro-
liferative condition compared with when cell culture
models are used; thus, they are in a physiological state
very similar to a blood vessel in the body. In addition,
there are multiple cell types in aorta section. Therefore,
the aortic ring assay is an ex vivo model that simulates
the real-life environment in which angiogenesis occurs
and involves all of the essential steps seen in angiogenesis,
including matrix degradation, migration, proliferation,
and reorganization (Staton et al., 2004; Auerbach et al.,
2003; Staton et al., 2009). Xanthomicrol and calycopterin
inhibited microvessel outgrowth in the rat aortas in a
concentration-dependent manner. Their effects on new
vessel formation were seen in a concentration range
over which they inhibited endothelial cell proliferation.
These flavones were more potent than suramin and
thalidomide in inhibiting microvessel sprouting in rat
aortas, which have been approved for clinical use as
inhibitors of angiogenesis for cancer treatment.
Many factors modulate new blood vessel sprouting
from rat aortic rings including presence of immune cells,
for example, phagocytes, smooth muscle cells, and also
cells from connective tissue (Zorzi et al., 2010).
However, as endothelial cells have a central role in the
angiogenic process, the effects of xanthomicrol and
calycopterin on migration and proliferation of these
cells were studied next. Endothelial cell tube formation
assay was used to study the effects of xanthomicrol and
calycopterin on cell migration. These flavones were able
to inhibit cell migration in a concentration-dependent
manner, although these effects appeared to reach a max-
imum at 10μg/mL. The effects of both these flavonoids
on tube formation occurred over a similar concentration
range as their inhibitory effects on HUVEC prolifera-
tion. Overall, the data presented so far support the idea
that these flavonoids can exert an antitumor effect over
a concentration range that is lower than that needed for
cytotoxic effects on most cancer cell lines tested.
At the molecular level, recent investigations have
clarified how many compounds with antiangiogenic
properties inhibit this physiological/pathologicalCopyright © 2014 John Wiley & Sons, Ltd.process. There are many angiogenic factors and en-
zymes involved in angiogenesis. VEGF is the most spe-
cific angiogenic factor with a potent effect on the
proliferation, migration, survival, and differentiation of
endothelial cells. b-FGF is one of the first angiogenic fac-
tors identified with an influence on proliferation, migra-
tion, and differentiation of endothelial cells (Liekens
et al., 2001).We found that xanthomicrol and calycopterin
inhibited VEGF expression in endothelial cells over the
same concentration range that had antiangiogenic effects
in the rat aortic ring and endothelial cell tube formation
assays. As VEGF is essential for endothelial cell prolifer-
ation and tube formation, this ‘selective’ effect of
xanthomicrol and calycopterin on VEGF expression
may suggest a mechanism for antiproliferative and
capillary tube formation inhibitory activity of these fla-
vones. The influences of these flavones on b-FGF
expression were negligible over the same concentration
range used for VEGF studies. This suggests that these fla-
vones change VEGF expression and thus affect
angiogenesis independently of their effects on b-FGF
expression.
It appears that a few polyphenolic compounds
selectively inhibit endothelial cell proliferation at low
concentration (Cao et al., 2002). This study also provides
a mechanistic insight into how polymethoxylated
flavones may inhibit angiogenesis.
Further studies are warranted to fully investigate the
mechanisms of antiangiogenic effect of xanthomicrol
and calycopterin. Such studies will indicate whether
the use of xanthomicrol and calycopterin is an effective
approach to control tumor progression and metastasis.
Especially important are studies on the in vivo
antiangiogenic activity of xanthomicrol and calycopterin
on tumor models.
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